ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

NameTrade nameCompanyClinical PhaseIndications
ustekinumab-auub; ABP 654WezlanaAmgenApproved (2023 FDA)As per reference agent; Interchangeable with reference agent
No information available.
Summary of Clinical Use Click here for help
Used to treat adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and is approved in the US to treat psoriatic arthritis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Ustekinumab binds to the IL-12B component of the dimeric cytokines IL-12 and IL-23. This action supresses the activation of certain T-cells, thereby dampening the immune response.
External links Click here for help